JON FAILLA: Open Payments
NPI 1326474685 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$60,855 in 101 payments from 8 companies in 2025. Trend: 2023 $2,063 · 2024 $7,850 · 2025 $60,855
Speaker / faculty: $44,240Consulting: $10,568Food & beverage: $3,837Travel & lodging: $2,211
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 40 | $34,488 |
| Teva Pharmaceuticals USA, Inc. | 22 | $14,301 |
| Alkermes, Inc. | 23 | $11,356 |
| E.R. Squibb & Sons, L.L.C. | 9 | $209 |
| Janssen Pharmaceuticals, Inc | 2 | $169 |
| Otsuka America Pharmaceutical, Inc. | 3 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $146 |
| ABBVIE INC. | 1 | $24 |
Products named: INGREZZA, UZEDY, LYBALVI, AUSTEDO XR, COBENFY, CAPLYTA, ABILIFY MAINTENA, SPRAVATO.
Industry payments across NV — which companies pay providers there.
